Digestive Disorders

The gastrointestinal tract—inflammatory bowel disease and irritable bowel syndrome

Many patient symptoms can be tied to multiple disorders, which may lead to misdiagnosis. For instance, consider two digestive disorders of the gastrointestinal tract—inflammatory bowel disease and irritable bowel syndrome. These two disorders are commonly confused because they present similar symptoms. As an advanced practice nurse, you must know the differences to properly diagnose and treat the disorders. How does the pathophysiology of inflammatory bowel disease compare to the pathophysiology of irritable bowel syndrome? How do treatments for the two disorders compare?

To Prepare

· Review Chapter 36 in the Huether and McCance text and Chapter 13 in the McPhee and Hammer text.

· Identify the pathophysiological mechanisms of inflammatory bowel disease and irritable bowel syndrome. Think about similarities and differences between the disorders.

· Consider common treatments for inflammatory bowel disease and irritable bowel syndrome. Reflect on whether treatments for one disorder would work for the other disorder.

· Select one of the following patient factors: genetics, gender, ethnicity. Reflect on how the factor you selected might impact the pathophysiology of and treatments for each disorder.

By Day 3

1. Post an explanation of the pathophysiological mechanisms of inflammatory bowel disorder and irritable bowel syndrome, including similarities and differences.
2. Then describe common treatments, addressing whether treatments for one disorder would work for the other disorder.
3. Finally, explain how the patient factor such as genetics, gender, or ethnicity,might impact the pathophysiology of and treatments for each disorder.

Student’s Name

Professor’s Name

Course

Date (day/month/year)

Digestive Disorders

The Gastrointestinal Tract—Inflammatory Bowel Disease and Irritable Bowel Syndrome

“From bloating to bowel irregularities, digestive disorders can cause discomfort and disruption to daily life, affecting millions worldwide.” Digestive disorders are conditions that affect the normal functioning of the digestive system (Ami D et al. 101). These disorders can occur at any point in the digestive process, from ingestion to elimination, leading to a wide range of symptoms such as bloating, constipation, diarrhea, abdominal pain, and nausea. Common digestive disorders include gastroesophageal reflux disease (GERD), irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), celiac disease, and peptic ulcer disease (Magdy et al. 788). These disorders can be caused by genetics, diet, stress, infections, and medication. Treatment for digestive disorders may involve lifestyle changes such as dietary modifications, stress reduction techniques, or medications to manage symptoms. In some cases, surgery may be necessary.

The gastrointestinal tract is a complex system responsible for digesting food, absorbing nutrients, and eliminating waste. Inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) are two common disorders that can affect the gastrointestinal tract (Hanlon et al. 250). IBD is a chronic inflammatory condition affecting any part of the gastrointestinal tract but most commonly involves the colon and small intestine. The two main types of IBD are Crohn’s disease and ulcerative colitis, which can cause symptoms such as abdominal pain, diarrhea, and rectal bleeding (Karen et al. 761). On the other hand, IBS is a functional disorder that affects the large intestine, causing symptoms such as abdominal pain, bloating, and changes in bowel habits. Unlike IBD, IBS does not cause inflammation or damage intestinal tissue. While the causes of these disorders are not entirely understood, they are thought to involve a combination of genetic, environmental, and lifestyle factors. Treatment options for both IBD and IBS include medication, dietary changes, and stress management techniques. The purpose of this essay is to compare and contrast the pathophysiology of inflammatory bowel disease and irritable bowel syndrome, including their common treatments, also, the essay will explore how a patient factor, such as genetics, gender, or ethnicity, might impact the pathophysiology of and treatments for each disorder. The goal is to give advanced practice nurses a deeper understanding of these two digestive disorders to diagnose and treat their patients properly.

The Pathophysiological Mechanisms of Inflammatory Bowel Disorder and Irritable Bowel Syndrome

Inflammatory bowel disorder (IBD) and Irritable bowel syndrome (IBS) are two separate gastrointestinal disorders that can cause significant discomfort and distress to individuals affected. IBD is a chronic autoimmune disease that involves inflammation of the digestive tract, while IBS is a functional disorder that affects the function of the digestive system without causing inflammation (Xin et al., 788). Both conditions have different pathophysiological mechanisms. In IBD, the immune system mistakenly attacks the lining of the digestive tract, leading to chronic inflammation. This inflammation can occur anywhere along the digestive tract, including the esophagus, stomach, small intestine, large intestine, and rectum. The exact cause of IBD is not fully understood, but it is thought to result from a combination of genetic and environmental factors. Specific genetic mutations can make an individual more susceptible to IBD, while environmental factors such as a high-fat diet, smoking, and stress can trigger or worsen symptoms. The chronic inflammation associated with IBD can lead to various complications, including ulcers, abscesses, and narrowing of the digestive tract (Gionata et al. 411). This narrowing can cause blockages and obstructions, leading to severe abdominal pain and diarrhea. The inflammation can also affect the absorption of nutrients, leading to malnutrition and other systemic complications. On the other hand, the pathophysiology of IBS is not fully understood. IBS is considered a functional disorder, meaning that there is no structural or biochemical abnormality causing the symptoms (Biljana et al. 2). Instead, IBS is thought to result from a combination of factors, including abnormal gut motility, visceral hypersensitivity, and altered brain-gut communication. Abnormal gut motility refers to irregular contractions of the digestive muscles, which can lead to symptoms such as constipation, diarrhea, and bloating. Visceral hypersensitivity refers to an increased sensitivity to normal intestinal stimuli, leading to abdominal pain and discomfort (Magnus et al. 16). Altered brain-gut communication refers to changes in how the brain and gut interact, leading to changes in the perception of intestinal sensations and motility. IBD and IBS are two separate gastrointestinal disorders with different pathophysiological mechanisms. IBD involves chronic inflammation of the digestive tract due to an autoimmune response, while IBS is a functional disorder that affects the function of the digestive system without causing inflammation. Understanding the pathophysiology of these conditions can help healthcare providers better diagnose and manage patients with these disorders.

Similarities between Inflammatory Bowel Disorder and Irritable Bowel Syndrome

Inflammatory bowel disorder (IBD) and irritable bowel syndrome (IBS) are gastrointestinal conditions that can cause significant discomfort and disrupt daily life. While the two disorders have distinct differences, there are also many similarities. One of the main similarities between IBD and IBS is that both conditions can cause symptoms such as abdominal pain, bloating, and diarrhea (Antonietta et al. 7). These symptoms can be severe and persistent difficult for people to go about their normal activities. In some cases, people with IBD or IBS may also experience constipation or a combination of constipation and diarrhea. Another similarity between the two conditions is that they can both be triggered or worsened by stress or anxiety. Emotional stress can cause physical changes in the gut, leading to flare-ups of symptoms in IBD and IBS (Boukje et al. 227). This connection between the gut and the brain is known as the gut-brain axis and is an area of ongoing research. Both IBD and IBS can also have a significant impact on a person’s quality of life. In addition to the physical symptoms, people with these conditions may experience social isolation, anxiety, and depression. The chronic nature of both disorders can also lead to missed work or school and decreased productivity. Finally, there is some overlap in the treatments used for IBD and IBS. For example, dietary changes and stress management techniques may be helpful for both conditions (Arthur et al. 7). Additionally, some medications used to treat IBD, such as anti-inflammatory drugs and immune system suppressors, may also be used to manage symptoms of IBS. While IBD and IBS are distinct conditions with their specific diagnostic criteria and treatment approaches, there are also many similarities. Both conditions can cause significant discomfort and disruption to daily life, and both may be triggered or worsened by stress or anxiety. Healthcare providers can better diagnose and treat patients with gastrointestinal symptoms by understanding the similarities and differences between these two conditions.

Differences between Inflammatory Bowel Disorder and Irritable Bowel Syndrome

Inflammatory Bowel Disorder (IBD) and Irritable Bowel Syndrome (IBS) are two common conditions that affect the digestive system, but they have distinct differences. IBD is a chronic inflammatory condition that affects the lining of the digestive tract (Rogatien et al. 8). The two main types of IBD are Crohn’s disease and ulcerative colitis. In Crohn’s disease, inflammation can occur anywhere along the digestive tract, from the mouth to the anus, while in ulcerative colitis, inflammation is limited to the large intestine and rectum. IBD is an autoimmune disorder, meaning that the immune system mistakenly attacks healthy cells in the digestive tract, leading to inflammation, ulcers, and other complications. Symptoms of IBD can include abdominal pain, diarrhea, rectal bleeding, weight loss, and fatigue (Krisztina et al., 647). Treatment for IBD can include medication, dietary changes, and severe cases, surgery. In contrast, IBS is a functional disorder that affects the muscular contractions of the digestive tract but does not involve inflammation (John et al. 149). The exact cause of IBS is unknown, but it is believed to be related to stress, diet, and abnormal gut bacteria. Symptoms of IBS can include abdominal pain, bloating, constipation, and diarrhea, varying in severity and frequency. Treatment for IBS can include dietary changes, stress management, and medication to relieve specific symptoms (John et al. 150). One of the critical differences between IBD and IBS is the presence or absence of inflammation in the digestive tract (Patrycja et al. 3). While IBD involves chronic inflammation and tissue damage, IBS does not involve inflammation and does not cause long-term damage to the digestive tract. Additionally, IBD is more severe and potentially life-threatening than IBS and requires more intensive treatment and management.

Common Treatments for Inflammatory Bowel Disorder and Irritable Bowel Syndrome

Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS) are different conditions affecting the digestive system, but they share some common symptoms. IBD is an autoimmune disease that causes chronic inflammation in the lining of the digestive tract, while IBS is a functional disorder that affects how the muscles in the bowel contract and relax (Alexander et al. 7). Although they have different causes, both conditions can cause abdominal pain, diarrhea, and other unpleasant symptoms. The treatments for IBD and IBS vary depending on the severity of the symptoms and the underlying cause of the condition. In general, the treatment of IBD aims to reduce inflammation and prevent complications, while the treatment of IBS aims to alleviate symptoms and improve quality of life (Jessica et al. 5). The most common treatments for IBD include medications that suppress the immune system and reduce inflammation. These medications include corticosteroids, immunomodulators, and biological agents. Some people with IBD also benefit from surgery, which can remove damaged digestive tract sections or create an ostomy to divert waste from the body (Muhammad 23). In addition to medical treatments, lifestyle modifications such as stress reduction, dietary changes, and regular exercise can also help manage IBD symptoms. For IBS, the treatments focus on relieving symptoms such as bloating, constipation, and diarrhea. These treatments include dietary changes, such as avoiding certain foods or increasing fibre intake, as well as medications that regulate bowel function. Some people with IBS also find relief from complementary therapies such as acupuncture, yoga, or hypnotherapy (Joana et al. 4). Psychological interventions, such as cognitive-behavioural therapy, can help reduce stress and improve IBS symptoms. In summary, IBD and IBS are different conditions with different causes but share some common symptoms. The treatments for IBD aim to reduce inflammation and prevent complications, while the treatments for IBS focus on alleviating symptoms and improving quality of life. Both conditions require medical treatments and lifestyle modifications to manage symptoms effectively.

Patient Factors that may impact the Pathophysiology of and Treatments for Inflammatory Bowel Disorder and Irritable Bowel Syndrome

The Impact of Genetic on the Pathophysiology of and Treatments for Inflammatory Bowel Disorder and Irritable Bowel Syndrome

Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS) are two different gastrointestinal disorders with similar symptoms but different pathophysiologies and treatments. Patient factors such as genetics can play a significant role in both disorders’ development, progression, and treatment outcomes. Inflammatory Bowel Disease (IBD) is a chronic inflammatory disorder of the gastrointestinal tract that includes two primary subtypes, Crohn’s disease (CD) and ulcerative colitis (UC). Genetics is a significant factor in the development of IBD, with some specific gene mutations or variations being associated with an increased risk of developing the disease (Bram et al. 2). For example, the NOD2/CARD15 gene is commonly associated with CD while variations in the HLA genes have been linked to UC. These genetic variants may impact the body’s immune response and increase inflammation in the gut, leading to the development of IBD. The impact of genetics on IBD also extends to its pathophysiology and clinical course (Yasser et al. 4). For instance, patients with CD who have a mutation in the NOD2/CARD15 gene are more likely to develop structuring or penetrating complications than those without the mutation. Similarly, patients with UC with variations in the HLA genes may be more likely to have more severe disease and require surgical intervention. These genetic factors can help clinicians tailor treatment approaches to the individual patient, such as using specific medications that target the underlying inflammatory process, including biological agents.

On the other hand, Irritable Bowel Syndrome (IBS) is a functional gastrointestinal disorder not associated with significant inflammation in the gut. However, genetics can still play a role in its development and progression. Several genes have been identified that may impact the gut-brain axis and contribute to symptoms such as abdominal pain, bloating, and altered bowel habits in patients with IBS (Maite and Åsa 4). For example, variations in the serotonin receptor gene (HTR3) have been linked to the development of diarrhea-predominant IBS, while variations in the guanylate cyclase-C receptor gene (GUCY2C) have been associated with constipation-predominant IBS. Genetic factors can also impact the response to treatment in patients with IBS (Magdy et al. 7). Certain genetic variations may impact the effectiveness of medications such as antidepressants, antispasmodics, or laxatives. As such, genetic testing may help clinicians tailor treatment approaches to the individual patient, such as selecting medications that are more likely to be effective based on the patient’s genetic profile. Genetic factors can significantly impact the pathophysiology of and treatments for Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS). Understanding these genetic factors can help clinicians tailor treatment approaches to the individual patient, improving treatment efficacy and reducing the risk of complications associated with these disorders.

The Impact of Gender on the Pathophysiology of and Treatments for Inflammatory Bowel Disorder and Irritable Bowel Syndrome

Inflammatory Bowel Disorder (IBD) and Irritable Bowel Syndrome (IBS) are gastrointestinal disorders affecting millions worldwide. Both disorders can cause significant discomfort, pain, and distress, and their pathophysiology is complex and multifactorial. One factor that may impact the pathophysiology and treatment of these disorders is the patient’s gender. Firstly, gender differences have been observed in the incidence and prevalence of IBD and IBS (Shun et al. 3). Research has shown that women are more likely to develop IBS than men, with a female-to-male ratio of about 2:1. Conversely, men are more likely to develop IBD, particularly Crohn’s disease, with a male-to-female ratio of about 1.5:1. The underlying reasons for these differences are not fully understood, but hormonal factors and genetic predisposition have been suggested. Secondly, gender may also affect the clinical presentation and course of IBD and IBS (Cai et al. 286). Women with IBS report more severe symptoms than men, such as abdominal pain, bloating, and constipation. In contrast, men with IBD may experience more severe disease activity and complications, such as strictures and fistulas. Additionally, women with IBD may experience disease flares during pregnancy, while men may experience more frequent surgical interventions. Lastly, the treatment of IBD and IBS may also be influenced by gender (Mohammad et al. 9). For example, women with IBD may face unique challenges during pregnancy, as certain medications used to treat IBD, such as methotrexate and azathioprine, can harm the developing fetus. As a result, treatment strategies for pregnant women with IBD must balance the risks to the mother and fetus. Similarly, the hormonal fluctuations that occur during menstruation and menopause may impact the effectiveness of specific treatments for IBS (Christine et al. 28). Gender is a patient factor that can impact the pathophysiology and treatment of IBD and IBS. While the reasons for these differences are not fully understood, healthcare providers should be aware of these potential gender-related factors when diagnosing and treating patients with these conditions. A personalized, patient-centred approach to care considering gender-related factors may help optimize outcomes for patients with IBD and IBS.

The Impact of Ethnicity on the Pathophysiology of and Treatments for Inflammatory Bowel Disorder and Irritable Bowel Syndrome

Ethnicity can play a significant role in the pathophysiology of Inflammatory Bowel Disorder (IBD) and Irritable Bowel Syndrome (IBS), as well as the effectiveness of treatments for these conditions. These conditions are characterized by chronic inflammation in the gastrointestinal tract, leading to various symptoms that can significantly impact quality of life. In IBD, ethnicity can impact the disease’s prevalence, severity, and progression (Edward et al. 679). For example, studies have shown that individuals of Ashkenazi Jewish descent are at a higher risk for developing IBD, particularly Crohn’s disease, than individuals of other ethnicities. Additionally, studies have suggested that African Americans and Hispanics may experience more severe disease and complications than Caucasians and may also have a different response to certain medications. For example, studies have shown that African Americans may respond less to infliximab, a commonly used medication for IBD, than Caucasians. Similarly, ethnicity can also impact the pathophysiology and treatment of IBS (Christopher et al. 9). Studies have shown that individuals of Asian descent may be more likely to experience specific symptoms, such as bloating and constipation, than individuals of other ethnicities. Additionally, studies have suggested that certain dietary factors may impact IBS symptoms differently in different ethnic groups. For example, studies have suggested that a high-fiber diet may be more effective in improving symptoms in Caucasians than in Asian Americans. Overall, ethnicity can impact the pathophysiology and treatment of IBD and IBS, highlighting the importance of considering individual patient factors when developing treatment plans. Healthcare providers should consider the patient’s ethnicity and other factors such as age, gender, and medical history when making treatment decisions for these conditions. Additionally, more research is needed to understand the impact of ethnicity on these conditions and to develop more effective and personalized treatments for individuals of different ethnicities.

Conclusion

In conclusion, digestive disorders such as inflammatory bowel disease and irritable bowel syndrome are complex and multifaceted conditions that can significantly impact a patient’s quality of life. While the pathophysiology of each disorder differs, they share similar symptoms, including abdominal pain, diarrhea, and constipation. Treatment options for these disorders include medication, dietary changes, and lifestyle modifications. However, it is essential to note that patient factors such as genetics, gender, and ethnicity may impact the pathophysiology and response to treatment for each disorder. Advanced practice nurses play a critical role in the diagnosis and management of these disorders and must have a thorough understanding of their pathophysiology and treatment options to provide optimal care to their patients.

 

 

 

 

 

 

 

 

 

 

 

 

 

Work Cited

Barnes, Edward L., Edward V. Loftus Jr, and Michael D. Kappelman. “Effects of race and ethnicity on diagnosis and management of inflammatory bowel diseases.” Gastroenterology 160.3 (2021): 677-689. https://doi.org/10.1053/j.gastro.2020.08.064

Black, Christopher J., and Alexander C. Ford. “Global burden of irritable bowel syndrome: trends, predictions and risk factors.” Nature reviews Gastroenterology & hepatology 17.8 (2020): 473-486.

Cai, W., J. Zhu, and D. Hu. “Clinical features and risk factors for ischemic colitis in young and middle-aged patients.” Acta Gastro-Enterologica Belgica 85 (2022).

Casado-Bedmar, Maite, and Åsa V. Keita. “Potential neuro-immune therapeutic targets in irritable bowel syndrome.” Therapeutic Advances in Gastroenterology 13 (2020): 1756284820910630.

Charlet, Rogatien, et al. “Remodeling of the Candida glabrata cell wall in the gastrointestinal tract affects the gut microbiota and the immune response.” Scientific Reports 8.1 (2018): 1-12.

El‑Salhy, Magdy, Odd Helge Gilja, and Jan Gunnar Hatlebakk. “Overlapping of irritable bowel syndrome with erosive esophagitis and the performance of Rome criteria in diagnosing IBS in a clinical setting.” Molecular medicine reports 20.1 (2019): 787-794.   https://doi.org/10.3892/mmr.2019.10284

El-Salhy, Magdy, Trygve Hausken, and Jan Gunnar Hatlebakk. “Increasing the dose and/or repeating faecal microbiota transplantation (FMT) increases the response in patients with irritable bowel syndrome (IBS).” Nutrients 11.6 (2019): 1415. https://doi.org/10.3390/nu11061415

Fiorino, Gionata, et al. “Impact of therapies on bowel damage in Crohn’s disease.” United European Gastroenterology Journal 8.4 (2020): 410-417.

Fitzpatrick, Jessica A., et al. “Dietary management of adults with IBD—the emerging role of dietary therapy.” Nature Reviews Gastroenterology & Hepatology 19.10 (2022): 652-669.

Ford, Alexander C., et al. “Functional dyspepsia.” The Lancet 396.10263 (2020): 1689-1702. https://doi.org/10.1016/S0140-6736(20)30469-4

Gecse, Krisztina B., and Severine Vermeire. “Differential diagnosis of inflammatory bowel disease: imitations and complications.” The Lancet Gastroenterology & Hepatology 3.9 (2018): 644-653. https://doi.org/10.1016/S2468-1253(18)30159-6

Gravina, Antonietta Gerarda, et al. “Adherence and effects derived from FODMAP diet on irritable bowel syndrome: a real life evaluation of a large follow-up observation.” Nutrients 12.4 (2020): 928. https://doi.org/10.3390/nu12040928

Hanlon, I., et al. “Systematic review with meta‐analysis: Online psychological interventions for mental and physical health outcomes in gastrointestinal disorders including irritable bowel syndrome and inflammatory bowel disease.” Alimentary Pharmacology & Therapeutics 48.3 (2018): 244-259. https://doi.org/10.1111/apt.14840

Jessa, Muhammad. “Case Study of Physiotherapy: Rehabilitation of patient after Ileostomy.” (2022). http://hdl.handle.net/20.500.11956/173058

Kemp, Karen, et al. “Second N-ECCO consensus statements on the European nursing roles in caring for patients with Crohn’s disease or ulcerative colitis.” Journal of Crohn’s and Colitis 12.7 (2018): 760-776. https://doi.org/10.1093/ecco-jcc/jjy020

Madla, Christine M., et al. “Let’s talk about sex: Differences in drug therapy in males and females.” Advanced Drug Delivery Reviews 175 (2021): 113804. https://doi.org/10.1016/j.addr.2021.05.014

Meng, Xin, et al. “Gut dysbacteriosis and intestinal disease: mechanism and treatment.” Journal of applied microbiology 129.4 (2020): 787-805. https://doi.org/10.1111/jam.14661

Morsy, Yasser, et al. “Unravelling the impact of the genetic variant rs1042058 within the TPL2 risk gene locus on molecular and clinical disease course patients with inflammatory bowel disease.” Cells 10.12 (2021): 3589. https://doi.org/10.3390/cells10123589

Nass, Boukje Yentl Sundari, Pauline Dibbets, and C. Rob Markus. “Impact of the COVID‐19 pandemic on inflammatory bowel disease: The role of emotional stress and social isolation.” Stress and Health 38.2 (2022): 222-233. https://doi.org/10.1002/smi.3080

Petitdemange, Arthur, et al. “Shared development of targeted therapies among autoimmune and inflammatory diseases: a systematic repurposing analysis.” Therapeutic advances in musculoskeletal disease 12 (2020): 1759720X20969261.

Radovanovic-Dinic, Biljana, et al. “Irritable bowel syndrome-from etiopathogenesis to therapy.” Biomedical Papers of the Medical Faculty of Palacky University in Olomouc 162.1 (2018). https://doi.org/10.5507/bp.2017.057

Simrén, Magnus, et al. “Cumulative effects of psychologic distress, visceral hypersensitivity, and abnormal transit on patient-reported outcomes in irritable bowel syndrome.” Gastroenterology 157.2 (2019): 391-402. https://doi.org/10.1053/j.gastro.2019.04.019

Sperber, Ami D., et al. “Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study.” Gastroenterology 160.1 (2021): 99-114. https://doi.org/10.1053/j.gastro.2020.04.014

Szałwińska, Patrycja, et al. “IBS-symptoms in IBD patients—manifestation of concomitant or different entities.” Journal of clinical medicine 10.1 (2020): 31. https://doi.org/10.3390/jcm10010031

Torres, Joana, et al. “European Crohn’s and Colitis Organisation topical review on complementary medicine and psychotherapy in inflammatory bowel disease.” Journal of Crohn’s and Colitis 13.6 (2019): 673-685e. https://doi.org/10.1093/ecco-jcc/jjz051

Verstockt, Bram, Kenneth GC Smith, and James C. Lee. “Genome‐wide association studies in Crohn’s disease: past, present and future.” Clinical & translational immunology 7.1 (2018): e1001. https://doi.org/10.1002/cti2.1001

Wallace, John L. “Nitric oxide in the gastrointestinal tract: opportunities for drug development.” British journal of pharmacology 176.2 (2019): 147-154. https://doi.org/10.1111/bph.14527

Yuan, Shun, et al. “Gender Differences in Damp-Heat Syndrome: A Review.” Biomedicine & Pharmacotherapy 143 (2021): 112128. https://doi.org/10.1016/j.biopha.2021.112128

Zamani, Mohammad, Shaghayegh Alizadeh‐Tabari, and Vahid Zamani. “Systematic review with meta‐analysis: the prevalence of anxiety and depression in patients with irritable bowel syndrome.” Alimentary pharmacology & therapeutics 50.2 (2019): 132-143. https://doi.org/10.1111/apt.15325

If you are having challenges with writing your nursing essay either because of lack of time or not knowing where to start, you can order your paper here